Peptide Therapy and Endocrinology: Understanding the Mechanism

Peptide therapy has moved from fringe biohacking territory into legitimate clinical investigation. If you're evaluating peptides for patients—or considering them yourself—you need to understand the endocrinology first.

The GH Axis and Peptide Signaling

Most peptides used in longevity and performance contexts work through the growth hormone-releasing hormone (GHRH) axis. Here's the mechanism:

GHRH agonists (like tesamorelin, hexarelin, or GHRP-6) bind to GH secretagogue receptors on anterior pituitary somatotroph cells. This triggers pulsatile growth hormone (GH) release. Unlike synthetic GH, which provides a flat supraphysiologic dose, peptide agonists preserve the body's natural GH pulsatility—releasing hormone at physiologically relevant times, typically 15–30 minutes after administration.

Why does pulsatility matter? Because GH signaling is time-dependent. Continuous GH exposure blunts insulin sensitivity and promotes mitochondrial stress. Pulsatile GH—the body's native pattern—optimizes IGF-1 production in the liver without the metabolic penalty.

IGF-1 is the downstream effector. It mediates most of GH's anabolic, recovery, and longevity benefits: collagen synthesis, muscle protein synthesis, bone mineral density, mitochondrial biogenesis, and cellular autophagy.

The Lab Framework Before Starting Peptide Therapy

Baseline testing is non-negotiable. You cannot interpret response without knowing starting values.

Core baseline panel:

• GH (fasting, AM): Reference range 0.4–4 ng/mL, but this is noise—single-point GH is unreliable due to episodic secretion. Use as context only.
• IGF-1: This is your primary metric. Reference range varies by age/sex (typically 83–213 ng/mL for adults 30–40), but optimal for longevity is upper tertile (190–230+ ng/mL). Many people run 20–50 ng/mL below their potential.
• Insulin fasting: <5 mIU/mL is ideal. HOMA-IR should be <1.5.
• Glucose (fasting): <95 mg/dL; <100 is reference but suboptimal for longevity.
• HbA1c: <5.5% is ideal; <5.3% is optimal metabolic health.
• Free and total testosterone: Critical baseline. Many men starting peptides are hypogonadal (total T <500 ng/dL, free T <10 pg/mL). Peptides can recruit endogenous T production, but you need to know the starting point.
• DHEA-S: This declines sharply with age. Baseline <100 mcg/dL suggests adrenal insufficiency; optimal is 150–250+.
• TSH, free T3, free T4: Peptides can upregulate thyroid function. Baseline hypothyroidism must be corrected first.
• Cortisol (AM): <10 mcg/dL is ideal. Elevated cortisol blunts GH secretion and inhibits IGF-1 signaling—therapeutic antagonism.
• Comprehensive metabolic panel, lipid panel, CBC: Safety baseline.

Optimal vs. Reference Ranges: Clinical Interpretation

This distinction is critical and often misunderstood.

Reference range (the gray zone printed on lab reports) represents the statistical spread of the general population. It does not mean optimal. A fasting glucose of 95 mg/dL is "normal"—it's inside the reference range—but it's metabolically suboptimal. A testosterone of 450 ng/dL is "normal" for a 45-year-old male, but it's inadequate for lean mass, bone density, and cognitive function.

Optimal range is where physiology runs best and disease risk is lowest. For IGF-1: optimal is upper quartile. For fasting insulin: optimal is <3.5 mIU/mL. For free testosterone: optimal is 15–20+ pg/mL for men.

When you start peptide therapy, you're optimizing toward the latter.

Synergistic Supplementation

Peptide response requires nutritional infrastructure. Consider baseline support:

Magnesium glycinate (400–500 mg daily): Magnesium is required for GH secretion and is depleted by peptides (especially GHRPs). Glycinate form reduces GI impact.

Vitamin D3/K2 (5,000 IU/100 mcg daily): D3 directly upregulates IGF-1 receptor expression in muscle. K2 (MK-7, 100+ mcg) is needed for bone mineralization—peptides increase osteoblast activity, but without K2 the calcium doesn't integrate.

Zinc (20–30 mg daily, not more): Zinc is cofactor for GH synthesis and IGF-1 signaling. Most people are marginally deficient. Excess suppresses copper and impairs immune function.

Omega-3 (2–3g EPA/DHA daily): Anti-inflammatory substrate for cell signaling. Peptides work on inflamed tissue less efficiently.

NAC (1–2g daily): Glutathione precursor. Peptides drive mitochondrial turnover; NAC supports detoxification.

Collagen (10–20g daily): Direct substrate. Peptides stimulate collagen synthesis, but if amino acid pools are depleted, the signal is wasted.

Ashwagandha (300–500 mg daily, standardized KSM-66): Lowers cortisol, which de-represses GH and IGF-1. Used clinically alongside GH therapy.

Berberine (500 mg 2–3x daily): Improves insulin sensitivity, which potentiates IGF-1 receptor signaling. Also activates AMPK, synergizing with GH's mitochondrial effects.

Methylated B vitamins (especially B12/folate as methylcobalamin/methylfolate): Peptide therapy increases anabolic demand. Methylated forms bypass genetic MTHFR variants.

Monitoring During Peptide Therapy

Retest 8–12 weeks in, then quarterly:

• IGF-1: Primary outcome metric. Target 190–250 ng/mL unless contraindicated. Do not exceed 250 without oncology clearance.
• Fasting insulin, glucose, HbA1c: Ensure glucose control remains stable. GH can induce insulin resistance in poorly controlled metabolisms—catch this early.
• Free and total testosterone: Peptides can boost LHRH signaling; you'll see secondary T elevation. Monitor for overshoot (total T >900, free T >25 pg/mL).
• TSH, free T3: Peptides often increase thyroid turnover. Baseline hypothyroidism may worsen; baseline euthyroidism may shift toward mild hyperthyroidism (fine, but monitor).
• Cortisol (AM): Should decline if stress management improves. Rising cortisol = therapy interference.
• Liver and kidney function: Quarterly AST, ALT, creatinine, BUN. Peptides are non-hepatotoxic, but you're tracking safety.

Bottom Line

Peptide therapy is a precision tool for modulating the GH axis within physiologic bounds. Success requires baseline endocrine mapping, clear understanding of reference vs. optimal ranges, nutritional scaffolding, and methodical monitoring. Endocrinologists trained in longevity medicine now view peptides as legitimate—not because they're magic, but because the mechanism is clean, the risk profile is low, and the clinical data supports IGF-1 optimization as a longevity variable.

The interview model your Leo Beauty Club endocrinologist followed is sound: mechanism first, then labs, then protocol, then patient selection. Follow that order.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.